PRESS RELEASE published on 08/20/2024 at 17:47, 1 year 8 months ago Terms of availability of the preparatory documents for the GM Medincell announces participation terms in the Combined General Meeting on September 12, 2024, including remote voting options, video conference for shareholders, and document availability Shareholders Combined General Meeting Remote Voting Medincell Participation Terms
BRIEF published on 06/28/2024 at 07:35, 1 year 10 months ago H.C. Wainwright & Co. Initiates MedinCell’s Coverage with "Buy" Recommendation FDA Approval BUY Rating Biopharmaceuticals H.C. Wainwright & Co. Medincell
PRESS RELEASE published on 06/28/2024 at 07:30, 1 year 10 months ago Inside Information / Other news releases H.C. Wainwright & Co. initiates coverage of MedinCell with a 'Buy' recommendation at €24 price target, reflecting +80% potential increase. MedinCell achieves milestones with FDA approvals, positive Phase 3 results, and collaboration with AbbVie FDA Approval Coverage Initiation H.C. Wainwright & Co. Medincell Pharmaceutical Sector
BRIEF published on 06/11/2024 at 09:05, 1 year 10 months ago Medincell Joins Euronext Tech Leaders Index Innovation Tech Sector Investor Visibility Medincell Euronext Tech Leaders
PRESS RELEASE published on 06/11/2024 at 09:00, 1 year 10 months ago Inside Information / Other news releases Medincell joins Euronext Tech Leaders, gaining access to a broad investor base and support services. CEO Christophe Douat highlights the company's growth and tech innovation leadership Tech Sector Financial Strategy Investor Base Medincell Euronext Tech Leaders
BRIEF published on 05/10/2024 at 18:05, 1 year 11 months ago Medincell announces details on capital and voting rights in accordance with regulations Euronext Paris Share Capital Voting Rights Financial Regulation Medincell
BRIEF published on 05/08/2024 at 12:35, 1 year 11 months ago Positive Results for the SOLARIS Phase 3 Trial of Olanzapine Schizophrenia Medincell SOLARIS Olanzapine TEV-'749
PRESS RELEASE published on 05/08/2024 at 12:30, 1 year 11 months ago Inside Information / Other news releases Teva and Medincell announce positive Phase 3 efficacy results from SOLARIS trial evaluating TEV-'749 (olanzapine) as a once-monthly subcutaneous long-acting injectable in adults with schizophrenia Schizophrenia Medincell Teva Phase 3 Efficacy Results SOLARIS Trial
BRIEF published on 05/08/2024 at 09:05, 1 year 11 months ago Medincell Temporarily Suspends its Euronext Paris Listing Euronext Paris Press Release Financial Markets Medincell Share Suspension
PRESS RELEASE published on 05/08/2024 at 09:00, 1 year 11 months ago Inside Information / Other news releases Medincell suspends listing of shares on Euronext Paris pending press release. Innovative biopharmaceutical company developing long-acting injectable drugs Euronext Paris Biopharmaceutical Suspension Medincell Long-acting Injectable Drugs
Published on 05/02/2026 at 01:30, 37 minutes ago Uraniumx Reports Strong Financial Position Ahead of Spring Drill Program
Published on 05/02/2026 at 00:50, 1 hour 17 minutes ago CoTec Announces Annual Stock Option, Restricted Share Unit And Deferred Share Unit Grants
Published on 05/02/2026 at 00:00, 2 hours 7 minutes ago Redwood AI Announces Enhanced AI Models, Increasing Evaluated Chemical Reactions Following Preliminary Results from UBC Collaboration
Published on 05/02/2026 at 00:00, 2 hours 7 minutes ago Onco-Innovations Expands Manufacturing Scale-Up of Its PNKP Inhibitor Technology with Dalton Pharma Services, Advancing Multi-Kilogram Non-GMP Synthesis to Support IND-Enabling Studies
Published on 05/01/2026 at 22:30, 3 hours 37 minutes ago Nextech3D.ai Appoints New Independent Auditor
Published on 05/01/2026 at 19:23, 6 hours 44 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 05/01/2026 at 17:45, 8 hours 22 minutes ago Burkhalter Group acquires Progressio Holding GmbH and anplaq ag, Tamins (GR)
Published on 05/01/2026 at 17:21, 8 hours 45 minutes ago Fuller, Smith & Turner PLC: Total Voting Rights and Treasury Shares
Published on 04/30/2026 at 20:00, 1 day 6 hours ago AMA Corp PLC : FY 2025 Earnings & Q1 2026 Revenue
Published on 04/30/2026 at 19:16, 1 day 6 hours ago AXA announces the results of its Shareholders' Meeting
Published on 04/30/2026 at 19:00, 1 day 7 hours ago Capital increase through exercise of subscription rights
Published on 04/30/2026 at 18:10, 1 day 7 hours ago Minutes of the Combined General Meeting held on April 30, 2026
